{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T23:45:24Z","timestamp":1790552724991,"version":"4.1.0"},"reference-count":138,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,10,7]],"date-time":"2020-10-07T00:00:00Z","timestamp":1602028800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001026","name":"National Breast Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell Dev. Biol."],"DOI":"10.3389\/fcell.2020.578770","type":"journal-article","created":{"date-parts":[[2020,10,7]],"date-time":"2020-10-07T01:09:16Z","timestamp":1602032956000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":57,"title":["Histone Deacetylases and Histone Deacetylase Inhibitors in Neuroblastoma"],"prefix":"10.3389","volume":"8","author":[{"given":"Monica","family":"Phimmachanh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy Z. R.","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yolande E. I.","family":"O\u2019Donnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharissa L.","family":"Latham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Croucher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,10,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/nrc2657","article-title":"p21 in cancer: intricate networks and multiple activities.","volume":"9","author":"Abbas","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"B2","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1126\/science.284.5415.770","article-title":"Notch signaling: cell fate control and signal integration in development.","volume":"284","author":"Artavanis-Tsakonas","year":"1999","journal-title":"Science"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a019521","article-title":"Histone modifications and cancer.","volume":"8","author":"Audia","year":"2016","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/cr.2011.22","article-title":"Regulation of chromatin by histone modifications.","volume":"21","author":"Bannister","year":"2011","journal-title":"Cell Res."},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-017-3126-7","article-title":"Acetazolamide potentiates the anti-tumor potential of HDACi, MS-275, in neuroblastoma.","volume":"17","author":"Bayat Mokhtari","year":"2017","journal-title":"BMC Cancer"},{"key":"B6","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1038\/nrd2133","article-title":"Anticancer activities of histone deacetylase inhibitors.","volume":"5","author":"Bolden","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"B7","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1038\/nrm2009","article-title":"Notch signalling: a simple pathway becomes complex.","volume":"7","author":"Bray","year":"2006","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s00441-017-2761-2","article-title":"Spontaneous regression of neuroblastoma.","volume":"372","author":"Brodeur","year":"2018","journal-title":"Cell Tissue Res."},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.4103\/0019-5154.160511","article-title":"Vorinostat-an overview.","volume":"60","author":"Bubna","year":"2015","journal-title":"Indian J. Dermatol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1158\/1078-0432.CCR-09-1865","article-title":"High frequency of p53\/MDM2\/p14ARF pathway abnormalities in relapsed neuroblastoma.","volume":"16","author":"Carr-Wilkinson","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"B11","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/s0092-8674(00)80516-4","article-title":"Nuclear receptor coactivator ACTR is a novel histone acetyltransferase and forms a multimeric activation complex with P\/CAF and CBP\/p300.","volume":"90","author":"Chen","year":"1997","journal-title":"Cell"},{"key":"B12","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/377454a0","article-title":"A transcriptional co-repressor that interacts with nuclear hormone receptors.","volume":"377","author":"Chen","year":"1995","journal-title":"Nature"},{"key":"B13","first-page":"2231","article-title":"Combined valproic acid and celecoxib treatment induced synergistic cytotoxicity and apoptosis in neuroblastoma cells.","volume":"31","author":"Chen","year":"2011","journal-title":"Anticancer Res."},{"key":"B14","first-page":"97","article-title":"Induction of differentiation and suppression of malignant phenotype of human neuroblastoma BE(2)-C cells by valproic acid: enhancement by combination with interferon-alpha.","volume":"20","author":"Cinatl","year":"2002","journal-title":"Int. J. Oncol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1111\/j.1582-4934.2011.01321.x","article-title":"Class IIa HDACs: from important roles in differentiation to possible implications in tumourigenesis.","volume":"15","author":"Clocchiatti","year":"2011","journal-title":"J. Cell. Mol. Med."},{"key":"B16","first-page":"3591","article-title":"The histone deacetylase inhibitor, CBHA, inhibits growth of human neuroblastoma xenografts in vivo, alone and synergistically with all-trans retinoic acid.","volume":"61","author":"Coffey","year":"2001","journal-title":"Cancer Res."},{"key":"B17","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1097\/CAD.0b013e32835dc7c5","article-title":"Valproic acid reduces the tolerability of temsirolimus in children and adolescents with solid tumors.","volume":"24","author":"Coulter","year":"2013","journal-title":"Anticancer Drugs"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1093\/carcin\/bgt124","article-title":"The chemopreventive activity of the butyric acid prodrug tributyrin in experimental rat hepatocarcinogenesis is associated with p53 acetylation and activation of the p53 apoptotic signaling pathway.","volume":"34","author":"de Conti","year":"2013","journal-title":"Carcinogenesis"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1158\/1535-7163.MCT-06-0623","article-title":"Combined effects of retinoic acid and histone deacetylase inhibitors on human neuroblastoma SH-SY5Y cells.","volume":"6","author":"De los Santos","year":"2007","journal-title":"Mol. Cancer Ther."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1016\/j.bcp.2004.05.010","article-title":"The novel histone deacetylase inhibitor BL1521 inhibits proliferation and induces apoptosis in neuroblastoma cells.","volume":"68","author":"de Ruijter","year":"2004","journal-title":"Biochem. Pharmacol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.yexcr.2005.06.024","article-title":"Gene expression profiling in response to the histone deacetylase inhibitor BL1521 in neuroblastoma.","volume":"309","author":"de Ruijter","year":"2005","journal-title":"Exp. Cell Res."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1038\/nn1102-1131","article-title":"The neurotrophin receptor p75(NTR): novel functions and implications for diseases of the nervous system.","volume":"5","author":"Dechant","year":"2002","journal-title":"Nat. Neurosci."},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s10495-020-01626-0","article-title":"Valproic acid upregulates the expression of the p75NTR\/sortilin receptor complex to induce neuronal apoptosis.","author":"Dedoni","year":"2020","journal-title":"Apoptosis"},{"key":"B24","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.canlet.2008.01.002","article-title":"Anti-neuroblastoma activity of Helminthosporium carbonum (HC)-toxin is superior to that of other differentiating compounds in vitro.","volume":"264","author":"Deubzer","year":"2008","journal-title":"Cancer Lett."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1002\/ijc.23295","article-title":"Histone deacetylase inhibitor Helminthosporium carbonum (HC)-toxin suppresses the malignant phenotype of neuroblastoma cells.","volume":"122","author":"Deubzer","year":"2008","journal-title":"Int. J. Cancer"},{"key":"B26","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s00383-012-3239-7","article-title":"The role of genetic and epigenetic alterations in neuroblastoma disease pathogenesis.","volume":"29","author":"Domingo-Fernandez","year":"2013","journal-title":"Pediatr. Surg. Int."},{"key":"B27","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.1158\/1078-0432.CCR-14-3240","article-title":"Phase I study of vorinostat as a radiation sensitizer with 131I-Metaiodobenzylguanidine (131I-MIBG) for patients with relapsed or refractory neuroblastoma.","volume":"21","author":"DuBois","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-017-0407-3","article-title":"Retinoic acid and TGF-beta signalling cooperate to overcome MYCN-induced retinoid resistance.","volume":"9","author":"Duffy","year":"2017","journal-title":"Genome Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1182\/blood-2006-06-025999","article-title":"Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL).","volume":"109","author":"Duvic","year":"2007","journal-title":"Blood"},{"key":"B30","doi-asserted-by":"publisher","first-page":"4103","DOI":"10.1016\/j.bmc.2010.03.080","article-title":"On the inhibition of histone deacetylase 8.","volume":"18","author":"Estiu","year":"2010","journal-title":"Bioorg. Med. Chem."},{"key":"B31","doi-asserted-by":"publisher","first-page":"66344","DOI":"10.18632\/oncotarget.11662","article-title":"MYCN and HDAC5 transcriptionally repress CD9 to trigger invasion and metastasis in neuroblastoma.","volume":"7","author":"Fabian","year":"2016","journal-title":"Oncotarget"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2020.112628","article-title":"Histone deacetylase inhibitor based prodrugs.","volume":"203","author":"Fan","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"B33","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/s1097-2765(03)00014-5","article-title":"Ligand-dependent nuclear receptor corepressor LCoR functions by histone deacetylase-dependent and -independent mechanisms.","volume":"11","author":"Fernandes","year":"2003","journal-title":"Mol. Cell"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.aab0990","article-title":"Signaling pathway models as biomarkers: patient-specific simulations of JNK activity predict the survival of neuroblastoma patients.","volume":"8","author":"Fey","year":"2015","journal-title":"Sci. Signal."},{"key":"B35","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/s41568-018-0003-x","article-title":"Too many targets, not enough patients: rethinking neuroblastoma clinical trials.","volume":"18","author":"Fletcher","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"B36","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/ng1531","article-title":"Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer.","volume":"37","author":"Fraga","year":"2005","journal-title":"Nat. Genet."},{"key":"B37","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.canlet.2011.11.036","article-title":"Histone deacetylase inhibition induces apoptosis and autophagy in human neuroblastoma cells.","volume":"318","author":"Francisco","year":"2012","journal-title":"Cancer Lett."},{"key":"B38","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.chembiol.2013.03.020","article-title":"Selective HDAC1\/HDAC2 inhibitors induce neuroblastoma differentiation.","volume":"20","author":"Frumm","year":"2013","journal-title":"Chem. Biol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1002\/ijc.22401","article-title":"Inhibitors of histone deacetylases as potential therapeutic tools for high-risk embryonal tumors of the nervous system of childhood.","volume":"120","author":"Furchert","year":"2007","journal-title":"Int. J. Cancer"},{"key":"B40","doi-asserted-by":"publisher","first-page":"2617","DOI":"10.1158\/0008-5472.CAN-04-3123","article-title":"Down-regulation of CD9 in human ovarian carcinoma cell might contribute to peritoneal dissemination: morphologic alteration and reduced expression of beta1 integrin subsets.","volume":"65","author":"Furuya","year":"2005","journal-title":"Cancer Res."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1182\/blood-2007-06-098061","article-title":"Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes.","volume":"111","author":"Garcia-Manero","year":"2008","journal-title":"Blood"},{"key":"B42","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.gene.2005.09.010","article-title":"Acetylation and deacetylation of non-histone proteins.","volume":"363","author":"Glozak","year":"2005","journal-title":"Gene"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1111\/j.1600-0463.2007.apm_636.xml.x","article-title":"Epigenetic changes in cancer.","volume":"115","author":"Gronbaek","year":"2007","journal-title":"APMIS"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1158\/0008-5472.can-03-0799","article-title":"Histone deacetylase is a target of valproic acid-mediated cellular differentiation.","volume":"64","author":"Gurvich","year":"2004","journal-title":"Cancer Res."},{"key":"B45","doi-asserted-by":"publisher","first-page":"9751","DOI":"10.1073\/pnas.0710413105","article-title":"Expression-based screening identifies the combination of histone deacetylase inhibitors and retinoids for neuroblastoma differentiation.","volume":"105","author":"Hahn","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0012825","article-title":"Differentiation in neuroblastoma: diffusion-limited hypoxia induces neuro-endocrine secretory protein 55 and other markers of a chromaffin phenotype.","volume":"5","author":"Hedborg","year":"2010","journal-title":"PLoS One"},{"key":"B47","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s11523-016-0420-2","article-title":"Dinutuximab: a review in high-risk neuroblastoma.","volume":"11","author":"Hoy","year":"2016","journal-title":"Target Oncol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"205","DOI":"10.2478\/v10102-009-0019-x","article-title":"Histone deacetylase inhibitors valproate and trichostatin A are toxic to neuroblastoma cells and modulate cytochrome P450 1A1, 1B1 and 3A4 expression in these cells.","volume":"2","author":"Hrebackova","year":"2009","journal-title":"Interdiscip. Toxicol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"3289","DOI":"10.1158\/1535-7163.MCT-10-0562","article-title":"Combination of vorinostat and flavopiridol is selectively cytotoxic to multidrug-resistant neuroblastoma cell lines with mutant TP53.","volume":"9","author":"Huang","year":"2010","journal-title":"Mol. Cancer Ther."},{"key":"B50","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1111\/jnc.14849","article-title":"Histone deacetylase 6 promotes growth of glioblastoma through the MKK7\/JNK\/c-Jun signaling pathway.","volume":"152","author":"Huang","year":"2020","journal-title":"J. Neurochem."},{"key":"B51","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1146\/annurev.pathol.3.121806.151442","article-title":"Epigenetic changes in cancer.","volume":"4","author":"Iacobuzio-Donahue","year":"2009","journal-title":"Annu. Rev. Pathol."},{"key":"B52","first-page":"6108","article-title":"MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors.","volume":"62","author":"Jaboin","year":"2002","journal-title":"Cancer Res."},{"key":"B53","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1126\/science.1104819","article-title":"Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy.","volume":"307","author":"Jain","year":"2005","journal-title":"Science"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-018-0077-2","article-title":"Targeting of epigenetic regulators in neuroblastoma.","volume":"50","author":"Jubierre","year":"2018","journal-title":"Exp. Mol. Med."},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-02242-4","article-title":"Targeting the CoREST complex with dual histone deacetylase and demethylase inhibitors.","volume":"9","author":"Kalin","year":"2018","journal-title":"Nat. Commun."},{"key":"B56","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3390\/cancers2020209","article-title":"Thioredoxin and cancer: a role for thioredoxin in all states of tumor oxygenation.","volume":"2","author":"Karlenius","year":"2010","journal-title":"Cancers"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1126\/science.1125950","article-title":"Antiangiogenic therapy: a universal chemosensitization strategy for cancer?","volume":"312","author":"Kerbel","year":"2006","journal-title":"Science"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1093\/jnci\/djm044","article-title":"Histone deacetylase 1 gene expression and sensitization of multidrug-resistant neuroblastoma cell lines to cytotoxic agents by depsipeptide.","volume":"99","author":"Keshelava","year":"2007","journal-title":"J. Natl. Cancer Inst."},{"key":"B59","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.1158\/1535-7163.MCT-09-0629","article-title":"Pharmacokinetics-pharmacodynamics and antitumor activity of mercaptoacetamide-based histone deacetylase inhibitors.","volume":"8","author":"Konsoula","year":"2009","journal-title":"Mol. Cancer Ther."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1016\/j.jpedsurg.2012.03.039","article-title":"Efficacy of class I and II vs class III histone deacetylase inhibitors in neuroblastoma.","volume":"47","author":"Lautz","year":"2012","journal-title":"J. Pediatr. Surg."},{"key":"B61","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.tig.2015.10.007","article-title":"Lateral thinking: how histone modifications regulate gene expression.","volume":"32","author":"Lawrence","year":"2016","journal-title":"Trends Genet."},{"key":"B62","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/B978-0-12-394387-3.00002-1","article-title":"Mechanisms of resistance to histone deacetylase inhibitors.","volume":"116","author":"Lee","year":"2012","journal-title":"Adv. Cancer Res."},{"key":"B63","doi-asserted-by":"publisher","first-page":"15704","DOI":"10.1073\/pnas.1313893110","article-title":"Development of a histone deacetylase 6 inhibitor and its biological effects.","volume":"110","author":"Lee","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-018-0654-9","article-title":"Histone deacetylase 6 in cancer.","volume":"11","author":"Li","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1016\/j.ejca.2009.03.002","article-title":"Over-expression of clusterin is a resistance factor to the anti-cancer effect of histone deacetylase inhibitors.","volume":"45","author":"Liu","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a018689","article-title":"Histone H3 mutations in pediatric brain tumors.","volume":"6","author":"Liu","year":"2014","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"6018","DOI":"10.1093\/nar\/gkt346","article-title":"MYCN and HDAC2 cooperate to repress miR-183 signaling in neuroblastoma.","volume":"41","author":"Lodrini","year":"2013","journal-title":"Nucleic Acids Res."},{"key":"B68","doi-asserted-by":"publisher","first-page":"25297","DOI":"10.1074\/jbc.M201869200","article-title":"Activation of the phosphatidylinositol 3-kinase\/Akt signaling pathway by retinoic acid is required for neural differentiation of SH-SY5Y human neuroblastoma cells.","volume":"277","author":"Lopez-Carballo","year":"2002","journal-title":"J. Biol. Chem."},{"key":"B69","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1515\/HMBCI.2011.020","article-title":"Sodium butyrate induces cellular senescence in neuroblastoma and prostate cancer cells.","volume":"7","author":"Lorenz","year":"2011","journal-title":"Horm. Mol. Biol. Clin. Investig."},{"key":"B70","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1016\/S0140-6736(07)60983-0","article-title":"Neuroblastoma.","volume":"369","author":"Maris","year":"2007","journal-title":"Lancet"},{"key":"B71","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.semcancer.2006.09.005","article-title":"Thioredoxin in cancer\u2013role of histone deacetylase inhibitors.","volume":"16","author":"Marks","year":"2006","journal-title":"Semin. Cancer Biol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1517\/13543784.2010.510514","article-title":"The clinical development of histone deacetylase inhibitors as targeted anticancer drugs.","volume":"19","author":"Marks","year":"2010","journal-title":"Expert Opin. Investig. Drugs"},{"key":"B73","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1002\/jcb.22185","article-title":"Histone deacetylase inhibitors: potential in cancer therapy.","volume":"107","author":"Marks","year":"2009","journal-title":"J. Cell Biochem."},{"key":"B74","doi-asserted-by":"publisher","first-page":"5957","DOI":"10.1038\/onc.2010.332","article-title":"Transcriptional upregulation of histone deacetylase 2 promotes Myc-induced oncogenic effects.","volume":"29","author":"Marshall","year":"2010","journal-title":"Oncogene"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1002135","article-title":"SIRT1 promotes N-Myc oncogenesis through a positive feedback loop involving the effects of MKP3 and ERK on N-Myc protein stability.","volume":"7","author":"Marshall","year":"2011","journal-title":"PLoS Genet."},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.3390\/genes11050556","article-title":"Histone deacetylases (HDACs): evolution, specificity, role in transcriptional complexes, and pharmacological actionability.","volume":"11","author":"Milazzo","year":"2020","journal-title":"Genes"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/514261","article-title":"Therapeutic strategies to enhance the anticancer efficacy of histone deacetylase inhibitors.","volume":"2011","author":"Miller","year":"2011","journal-title":"J. Biomed. Biotechnol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"35545","DOI":"10.1074\/jbc.M505630200","article-title":"A specific microdomain (\u201cglycosynapse 3\u201d) controls phenotypic conversion and reversion of bladder cancer cells through GM3-mediated interaction of alpha3beta1 integrin with CD9.","volume":"280","author":"Mitsuzuka","year":"2005","journal-title":"J. Biol. Chem."},{"key":"B79","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1038\/s41591-019-0376-8","article-title":"Targeting epigenetic modifications in cancer therapy: erasing the roadmap to cancer.","volume":"25","author":"Mohammad","year":"2019","journal-title":"Nat. Med."},{"key":"B80","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.canlet.2011.03.010","article-title":"Cooperation of the HDAC inhibitor vorinostat and radiation in metastatic neuroblastoma: efficacy and underlying mechanisms.","volume":"306","author":"Mueller","year":"2011","journal-title":"Cancer Lett."},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-6-214","article-title":"Histone deacetylase inhibitors strongly sensitise neuroblastoma cells to TRAIL-induced apoptosis by a caspases-dependent increase of the pro- to anti-apoptotic proteins ratio.","volume":"6","author":"Muhlethaler-Mottet","year":"2006","journal-title":"BMC Cancer"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-7-55","article-title":"Complex molecular mechanisms cooperate to mediate histone deacetylase inhibitors anti-tumour activity in neuroblastoma cells.","volume":"7","author":"Muhlethaler-Mottet","year":"2008","journal-title":"Mol. Cancer"},{"key":"B83","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1002\/pbc.24271","article-title":"A phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid tumors: a children\u2019s oncology group phase I consortium study (ADVL0916).","volume":"60","author":"Muscal","year":"2013","journal-title":"Pediatr. Blood Cancer"},{"key":"B84","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1158\/1078-0432.CCR-15-2388","article-title":"c-Myc modulation and acetylation is a key HDAC inhibitor target in cancer.","volume":"23","author":"Nebbioso","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"B85","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1158\/1078-0432.CCR-08-0684","article-title":"Histone deacetylase 8 in neuroblastoma tumorigenesis.","volume":"15","author":"Oehme","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"B86","doi-asserted-by":"publisher","first-page":"E2592","DOI":"10.1073\/pnas.1300113110","article-title":"Histone deacetylase 10 promotes autophagy-mediated cell survival.","volume":"110","author":"Oehme","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B87","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.semcancer.2011.07.002","article-title":"Progress in treatment and risk stratification of neuroblastoma: impact on future clinical and basic research.","volume":"21","author":"Ora","year":"2011","journal-title":"Semin. Cancer Biol."},{"key":"B88","doi-asserted-by":"publisher","first-page":"24339","DOI":"10.18632\/oncotarget.8248","article-title":"Suppressing activity of tributyrin on hepatocarcinogenesis is associated with inhibiting the p53-CRM1 interaction and changing the cellular compartmentalization of p53 protein.","volume":"7","author":"Ortega","year":"2016","journal-title":"Oncotarget"},{"key":"B89","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1016\/j.febslet.2005.01.058","article-title":"Histone deacetylase inhibitor BL1521 induces a G1-phase arrest in neuroblastoma cells through altered expression of cell cycle proteins.","volume":"579","author":"Ouwehand","year":"2005","journal-title":"FEBS Lett."},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01355","article-title":"A comprehensive safety trial of chimeric antibody 14.18 with GM-CSF, IL-2, and isotretinoin in high-risk neuroblastoma patients following myeloablative therapy: children\u2019s oncology group study ANBL0931.","volume":"9","author":"Ozkaynak","year":"2018","journal-title":"Front. Immunol."},{"key":"B91","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.4161\/cc.9.9.11543","article-title":"Romidepsin (FK228\/depsipeptide) controls growth and induces apoptosis in neuroblastoma tumor cells.","volume":"9","author":"Panicker","year":"2010","journal-title":"Cell Cycle"},{"key":"B92","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1102\/1470-7330.2005.0104","article-title":"Neuroblastoma in childhood: review and radiological findings.","volume":"5","author":"Papaioannou","year":"2005","journal-title":"Cancer Imaging"},{"key":"B93","doi-asserted-by":"publisher","first-page":"889","DOI":"10.3892\/ijo.12.4.889","article-title":"Cytotoxic effects of sodium phenylbutyrate on human neuroblastoma cell lines.","volume":"12","author":"Pelidis","year":"1998","journal-title":"Int. J. Oncol."},{"key":"B94","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/nrd.2016.256","article-title":"Marked for death: targeting epigenetic changes in cancer.","volume":"16","author":"Pfister","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"B95","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1215\/S1152851704000183","article-title":"Oral sodium phenylbutyrate in patients with recurrent malignant gliomas: a dose escalation and pharmacologic study.","volume":"7","author":"Phuphanich","year":"2005","journal-title":"Neuro Oncol."},{"key":"B96","doi-asserted-by":"publisher","first-page":"4636","DOI":"10.1182\/blood-2003-09-3068","article-title":"T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance.","volume":"103","author":"Piekarz","year":"2004","journal-title":"Blood"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.27023","article-title":"Phase I study of vorinostat in combination with isotretinoin in patients with refractory\/recurrent neuroblastoma: a new approaches to Neuroblastoma Therapy (NANT) trial.","volume":"65","author":"Pinto","year":"2018","journal-title":"Pediatr. Blood Cancer"},{"key":"B98","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.bbrc.2012.06.125","article-title":"PI3K\/AKT and ERK regulate retinoic acid-induced neuroblastoma cellular differentiation.","volume":"424","author":"Qiao","year":"2012","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2015.24","article-title":"Selective inhibition of HDAC8 decreases neuroblastoma growth in vitro and in vivo and enhances retinoic acid-mediated differentiation.","volume":"6","author":"Rettig","year":"2015","journal-title":"Cell Death Dis."},{"key":"B100","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/s0304-3835(03)00108-3","article-title":"Retinoid therapy of high-risk neuroblastoma.","volume":"197","author":"Reynolds","year":"2003","journal-title":"Cancer Lett."},{"key":"B101","doi-asserted-by":"publisher","first-page":"3003","DOI":"10.1073\/pnas.95.6.3003","article-title":"A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases.","volume":"95","author":"Richon","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B102","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1021\/mp200329f","article-title":"Histone deacetylase inhibitors: emerging mechanisms of resistance.","volume":"8","author":"Robey","year":"2011","journal-title":"Mol. Pharm."},{"key":"B103","first-page":"1099","article-title":"Effect of butyrate analogues on proliferation and differentiation in human neuroblastoma cell lines.","volume":"18","author":"Rocchi","year":"1998","journal-title":"Anticancer Res."},{"key":"B104","first-page":"917","article-title":"Growth inhibitory and differentiating effects of sodium butyrate on human neuroblastoma cells in culture.","volume":"12","author":"Rocchi","year":"1992","journal-title":"Anticancer Res."},{"key":"B105","first-page":"1139","article-title":"p21Waf1\/Cip1 is a common target induced by short-chain fatty acid HDAC inhibitors (valproic acid, tributyrin and sodium butyrate) in neuroblastoma cells.","volume":"13","author":"Rocchi","year":"2005","journal-title":"Oncol. Rep."},{"key":"B106","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/ng1773","article-title":"A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition.","volume":"38","author":"Ropero","year":"2006","journal-title":"Nat. Genet."},{"key":"B107","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.pneurobio.2005.10.006","article-title":"The p75 neurotrophin receptor in human development and disease.","volume":"77","author":"Schor","year":"2005","journal-title":"Prog. Neurobiol."},{"key":"B108","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1038\/ng.3349","article-title":"Mutational dynamics between primary and relapse neuroblastomas.","volume":"47","author":"Schramm","year":"2015","journal-title":"Nat. Genet."},{"key":"B109","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/305245a0","article-title":"Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour.","volume":"305","author":"Schwab","year":"1983","journal-title":"Nature"},{"key":"B110","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1097\/JTO.0b013e318220caff","article-title":"Histone deacetylase inhibitors sensitize human non-small cell lung cancer cells to ionizing radiation through acetyl p53-mediated c-myc down-regulation.","volume":"6","author":"Seo","year":"2011","journal-title":"J. Thorac. Oncol."},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.7243\/2049-7962-2-21","article-title":"PCI-24781 (abexinostat), a novel histone deacetylase inhibitor, induces reactive oxygen species-dependent apoptosis and is synergistic with bortezomib in neuroblastoma.","volume":"2","author":"Sholler","year":"2013","journal-title":"J. Cancer Ther. Res."},{"key":"B112","doi-asserted-by":"publisher","first-page":"241","DOI":"10.3109\/08923973.2010.521507","article-title":"All trans retinoic acid and cancer.","volume":"33","author":"Siddikuzzaman, Guruvayoorappan","year":"2011","journal-title":"Immunopharmacol. Immunotoxicol."},{"key":"B113","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1038\/sj.bjc.6602309","article-title":"Effects of the histone deacetylase inhibitor valproic acid on Notch signalling in human neuroblastoma cells.","volume":"92","author":"Stockhausen","year":"2005","journal-title":"Br. J. Cancer"},{"key":"B114","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1593\/neo.11558","article-title":"HDAC6 deacetylates Ku70 and regulates Ku70-Bax binding in neuroblastoma.","volume":"13","author":"Subramanian","year":"2011","journal-title":"Neoplasia"},{"key":"B115","doi-asserted-by":"publisher","first-page":"4842","DOI":"10.1073\/pnas.0408351102","article-title":"Ku70 acetylation mediates neuroblastoma cell death induced by histone deacetylase inhibitors.","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B116","doi-asserted-by":"publisher","first-page":"2987","DOI":"10.1038\/onc.2013.253","article-title":"Histone deacetylase 5 blocks neuroblastoma cell differentiation by interacting with N-Myc.","volume":"33","author":"Sun","year":"2014","journal-title":"Oncogene"},{"key":"B117","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1042\/CS20120504","article-title":"Histone deacetylases as targets for treatment of multiple diseases.","volume":"124","author":"Tang","year":"2013","journal-title":"Clin. Sci."},{"key":"B118","doi-asserted-by":"publisher","first-page":"5837","DOI":"10.1158\/1078-0432.CCR-04-0395","article-title":"Favorable neuroblastoma genes and molecular therapeutics of neuroblastoma.","volume":"10","author":"Tang","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"B119","first-page":"8948","article-title":"Induction of PIG3 and NOXA through acetylation of p53 at 320 and 373 lysine residues as a mechanism for apoptotic cell death by histone deacetylase inhibitors.","volume":"63","author":"Terui","year":"2003","journal-title":"Cancer Res."},{"key":"B120","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1182\/blood.V118.21.2461.2461","article-title":"Acetylation of p53 is involved in valproic acid induced death of AML cells.","volume":"118","author":"Thakur","year":"2011","journal-title":"Blood"},{"key":"B121","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1111\/j.1749-6632.2003.tb05964.x","article-title":"Histone deacetylases: unique players in shaping the epigenetic histone code.","volume":"983","author":"Thiagalingam","year":"2003","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"B122","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.canlet.2012.08.017","article-title":"Towards a turning point of neuroblastoma therapy.","volume":"326","author":"Tonini","year":"2012","journal-title":"Cancer Lett."},{"key":"B123","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.biopha.2007.06.002","article-title":"Romidepsin (depsipeptide) induced cell cycle arrest, apoptosis and histone hyperacetylation in lung carcinoma cells (A549) are associated with increase in p21 and hypophosphorylated retinoblastoma proteins expression.","volume":"62","author":"Vinodhkumar","year":"2008","journal-title":"Biomed. Pharmacother."},{"key":"B124","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1002\/ijc.30056","article-title":"Long term, continuous exposure to panobinostat induces terminal differentiation and long term survival in the TH-MYCN neuroblastoma mouse model.","volume":"139","author":"Waldeck","year":"2016","journal-title":"Int. J. Cancer"},{"key":"B125","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.ceb.2013.01.001","article-title":"Targeting histone modifications\u2013epigenetics in cancer.","volume":"25","author":"Waldmann","year":"2013","journal-title":"Curr. Opin. Cell Biol."},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0076662","article-title":"Panobinostat synergistically enhances the cytotoxic effects of cisplatin, doxorubicin or etoposide on high-risk neuroblastoma cells.","volume":"8","author":"Wang","year":"2013","journal-title":"PLoS One"},{"key":"B127","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1002\/ijc.32321","article-title":"MKK7 transcription positively or negatively regulated by SP1 and KLF5 depends on HDAC4 activity in glioma.","volume":"145","author":"Wang","year":"2019","journal-title":"Int. J. Cancer"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-016-0225-2","article-title":"Histone acetyltransferases: challenges in targeting bi-substrate enzymes.","volume":"8","author":"Wapenaar","year":"2016","journal-title":"Clin. Epigenet."},{"key":"B129","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1097\/CAD.0b013e32830efbeb","article-title":"HKI 46F08, a novel potent histone deacetylase inhibitor, exhibits antitumoral activity against embryonic childhood cancer cells.","volume":"19","author":"Wegener","year":"2008","journal-title":"Anticancer Drugs"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2019.00468","article-title":"Inhibition of HDAC4 attenuated JNK\/c-Jun-dependent neuronal apoptosis and early brain injury following subarachnoid hemorrhage by transcriptionally suppressing MKK7.","volume":"13","author":"Wu","year":"2019","journal-title":"Front. Cell Neurosci."},{"key":"B131","doi-asserted-by":"publisher","first-page":"5541","DOI":"10.1038\/sj.onc.1210620","article-title":"Histone deacetylase inhibitors: molecular mechanisms of action.","volume":"26","author":"Xu","year":"2007","journal-title":"Oncogene"},{"key":"B132","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1158\/0008-5472.CAN-06-2595","article-title":"Thrombospondin-1 peptide ABT-510 combined with valproic acid is an effective antiangiogenesis strategy in neuroblastoma.","volume":"67","author":"Yang","year":"2007","journal-title":"Cancer Res."},{"key":"B133","doi-asserted-by":"publisher","first-page":"2873","DOI":"10.1128\/MCB.25.8.2873-2884.2005","article-title":"Class II histone deacetylases: from sequence to function, regulation, and clinical implication.","volume":"25","author":"Yang","year":"2005","journal-title":"Mol. Cell Biol."},{"key":"B134","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.4161\/15384047.2014.956632","article-title":"HDAC6 regulates neuroblastoma cell migration and may play a role in the invasion process.","volume":"15","author":"Zhang","year":"2014","journal-title":"Cancer Biol. Ther."},{"key":"B135","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1128\/MCB.26.7.2782-2790.2006","article-title":"Acetylation of p53 at lysine 373\/382 by the histone deacetylase inhibitor depsipeptide induces expression of p21(Waf1\/Cip1).","volume":"26","author":"Zhao","year":"2006","journal-title":"Mol. Cell Biol."},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-019-1870-5","article-title":"Epigenetic modifications of histones in cancer.","volume":"20","author":"Zhao","year":"2019","journal-title":"Genome Biol."},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2013.264","article-title":"Differential effect of long-term drug selection with doxorubicin and vorinostat on neuroblastoma cells with cancer stem cell characteristics.","volume":"4","author":"Zheng","year":"2013","journal-title":"Cell Death Dis."},{"key":"B138","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1158\/2159-8290.CD-17-0993","article-title":"MYC drives a subset of high-risk pediatric neuroblastomas and is activated through mechanisms including enhancer hijacking and focal enhancer amplification.","volume":"8","author":"Zimmerman","year":"2018","journal-title":"Cancer Discov"}],"container-title":["Frontiers in Cell and Developmental Biology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fcell.2020.578770\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,7]],"date-time":"2020-10-07T01:09:24Z","timestamp":1602032964000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fcell.2020.578770\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,7]]},"references-count":138,"alternative-id":["10.3389\/fcell.2020.578770"],"URL":"https:\/\/doi.org\/10.3389\/fcell.2020.578770","relation":{},"ISSN":["2296-634X"],"issn-type":[{"value":"2296-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,7]]},"article-number":"578770"}}